JP2008532974A5 - - Google Patents

Download PDF

Info

Publication number
JP2008532974A5
JP2008532974A5 JP2008500172A JP2008500172A JP2008532974A5 JP 2008532974 A5 JP2008532974 A5 JP 2008532974A5 JP 2008500172 A JP2008500172 A JP 2008500172A JP 2008500172 A JP2008500172 A JP 2008500172A JP 2008532974 A5 JP2008532974 A5 JP 2008532974A5
Authority
JP
Japan
Prior art keywords
diabetes
pharmaceutically acceptable
acceptable salt
type
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532974A (ja
JP5091106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/060418 external-priority patent/WO2006094933A1/en
Publication of JP2008532974A publication Critical patent/JP2008532974A/ja
Publication of JP2008532974A5 publication Critical patent/JP2008532974A5/ja
Application granted granted Critical
Publication of JP5091106B2 publication Critical patent/JP5091106B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008500172A 2005-03-08 2006-03-03 真性糖尿病の治療のためのロフルミラスト Expired - Fee Related JP5091106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101772.1 2005-03-08
EP05101772 2005-03-08
PCT/EP2006/060418 WO2006094933A1 (en) 2005-03-08 2006-03-03 Roflumilast for the treatment of diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012129982A Division JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Publications (3)

Publication Number Publication Date
JP2008532974A JP2008532974A (ja) 2008-08-21
JP2008532974A5 true JP2008532974A5 (https=) 2009-04-30
JP5091106B2 JP5091106B2 (ja) 2012-12-05

Family

ID=34938922

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500172A Expired - Fee Related JP5091106B2 (ja) 2005-03-08 2006-03-03 真性糖尿病の治療のためのロフルミラスト
JP2012129982A Expired - Fee Related JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012129982A Expired - Fee Related JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Country Status (15)

Country Link
US (2) US8017633B2 (https=)
EP (1) EP1874308A1 (https=)
JP (2) JP5091106B2 (https=)
KR (1) KR101302838B1 (https=)
CN (2) CN102600144A (https=)
AU (1) AU2006222060B2 (https=)
BR (1) BRPI0609371A2 (https=)
CA (1) CA2599376C (https=)
EA (1) EA015382B1 (https=)
IL (2) IL185277A (https=)
MX (1) MX2007010560A (https=)
NO (1) NO20074943L (https=)
NZ (1) NZ560269A (https=)
WO (1) WO2006094933A1 (https=)
ZA (1) ZA200706294B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3993169B2 (ja) 2002-02-11 2007-10-17 アンタレス・ファーマ・インコーポレーテッド 皮内注射器
JP5216328B2 (ja) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド あらかじめ充填された針補助シリンジジェット式注射器
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
JP2010502670A (ja) * 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
EP2268342B1 (en) 2008-03-10 2015-09-16 Antares Pharma, Inc. Injector safety device
CN101548972B (zh) * 2008-04-03 2012-10-17 万特制药(海南)有限公司 一种含有瑞格列奈的固体药物组合物
EP3581224A1 (en) 2008-08-05 2019-12-18 Antares Pharma, Inc. Multiple dosage injector
CN102612381B (zh) 2009-03-20 2015-09-09 安塔瑞斯制药公司 危险试剂注入系统
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
WO2013134244A2 (en) 2012-03-06 2013-09-12 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
ES2969984T3 (es) 2013-02-11 2024-05-23 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
JP6030803B2 (ja) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド ピニオンシステムを有する用量注射器
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
EP3165224A1 (en) * 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB202306663D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
EP0671936A1 (en) 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
KR970705562A (ko) 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
UA48216C2 (uk) 1996-01-31 2002-08-15 Бік Гулден Ломберг Кеміше Фабрік Гмбх Фенантридини та лікарський засіб для лікування захворювань дихальних шляхів
DE19617864A1 (de) 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE59811840D1 (de) 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
ATE294793T1 (de) 1999-01-15 2005-05-15 Altana Pharma Ag Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
EP1650193A3 (en) 1999-01-15 2006-10-04 ALTANA Pharma AG 6-Phenylphenanthridines with PDE-IV inhibiting activity
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001035979A2 (en) 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
US6642250B2 (en) 1999-12-08 2003-11-04 Grelan Pharmaceutical Co., Ltd. 1,8-naphthyridin-2(1H)-one derivatives
AU2001250820A1 (en) 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002013798A2 (en) 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
BR0113167A (pt) 2000-08-11 2003-06-24 Ono Pharmaceutical Co Derivados de piperidina e agente que compreende o derivado como ingrediente ativo
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
WO2002060898A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
JP2005506286A (ja) * 2001-03-02 2005-03-03 ブリストル−マイヤーズ スクイブ カンパニー サイクリック−amp関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
ME00565A (en) * 2002-05-28 2011-12-20 Topically applicable pharmaceutical preparation
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
EA012279B1 (ru) * 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
WO2005020926A2 (en) * 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2005041864A2 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
WO2005116653A2 (en) 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus

Similar Documents

Publication Publication Date Title
JP2008532974A5 (https=)
JP2008543776A5 (https=)
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
JP2009529541A5 (https=)
JP2009506094A5 (https=)
JP2008528441A5 (https=)
JP2009514837A5 (https=)
PH12016502294A1 (en) Novel fatty acids and their use in conjugation to biomolecules
JP2009501178A5 (https=)
NZ598323A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
JP2008007519A5 (https=)
RU2010120808A (ru) Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
EP1726580A4 (en) AMINOPHNYLPROPANO ACID DERIVATIVE
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2007131005A3 (en) Use of organic compounds
JP2009514835A5 (https=)
WO2007104789A3 (en) Amylin derivatives
JP2009538898A5 (https=)
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
NZ594244A (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
RU2019111421A (ru) Способы лечения острого повреждения почек
RU2015142255A (ru) Фармацевтическое комбинированное лекарственное средство
JP2018502135A5 (https=)
JP2019151627A5 (https=)